Literature DB >> 8609405

Effect of the IgM and IgA secretory tailpieces on polymerization and secretion of IgM and IgG.

V Sørensen1, I B Rasmussen, L Norderhaug, I Natvig, T E Michaelsen, I Sandlie.   

Abstract

Pentameric IgM and dimeric IgA both contain disulfide bonds between cysteines located in the secretory tailpieces of the heavy chains. To compare the influences of the mu and alpha tailpieces on the polymeric structure, we have replaced amino acids in the tailpiece of the human mu-chain with amino acids found in the corresponding positions in the human alpha tailpiece. We show that an IgM with an alpha tailpiece (IgM L561H, Y562V, L566V, S569A, D570E, T571V, and A572D) as well as IgM L561H, Y562V, and IgM A572D have a size distribution similar to that of wild-type IgM. However, one IgM mutant with a mu/alpha hybrid tailpiece (IgM L566V, S569A, D570E, T571V, and A572D) is secreted as a mixture of mainly hexamers, pentamers, tetramers, and dimers. The tetramers and dimers are specifically formed and secreted at the expense of pentamers and hexamers; no alterations in polymerization or secretion rates were observed. We have also incorporated the mu, alpha, and hybrid mu/alpha tailpieces to a human IgG3 or IgGL309C mutant. The IgG-tailpiece mutants are poorly secreted, but the secreted fractions contain multimeric molecules. Each of the mutants that contain both the L309C mutation and a secretory tailpiece forms mainly hexamers; however, small differences in polymer distribution exist for the different tailpieces. Comparison of the influence of different tailpieces on IgM and IgG polymeric structures suggests that the function of a specific tailpiece is dependent on other parts of the heavy chain, which can vary for different isotypes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8609405

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2.

Authors:  Susan E Hiby; Richard Apps; Andrew M Sharkey; Lydia E Farrell; Lucy Gardner; Arend Mulder; Frans H Claas; James J Walker; Christopher W Redman; Christopher C Redman; Linda Morgan; Clare Tower; Lesley Regan; Gudrun E Moore; Mary Carrington; Ashley Moffett
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

2.  MZB1 promotes the secretion of J-chain-containing dimeric IgA and is critical for the suppression of gut inflammation.

Authors:  Ermeng Xiong; Yingqian Li; Qing Min; Chaoqun Cui; Jun Liu; Rongjian Hong; Nannan Lai; Ying Wang; Jiping Sun; Ryohtaroh Matsumoto; Daisuke Takahashi; Koji Hase; Reiko Shinkura; Takeshi Tsubata; Ji-Yang Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-24       Impact factor: 11.205

3.  A peptide extension dictates IgM assembly.

Authors:  Dzana Pasalic; Benedikt Weber; Chiara Giannone; Tiziana Anelli; Roger Müller; Claudio Fagioli; Manuel Felkl; Christine John; Maria Francesca Mossuto; Christian F W Becker; Roberto Sitia; Johannes Buchner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-27       Impact factor: 11.205

4.  Influence of the mu-chain C-terminal sequence on polymerization of immunoglobulin M.

Authors:  A Getahun; M Lundqvist; D Middleton; G Warr; L Pilström
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

5.  TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.

Authors:  Xiuhong Piao; Tatsuhiko Ozawa; Hiroshi Hamana; Kiyomi Shitaoka; Aishun Jin; Hiroyuki Kishi; Atsushi Muraguchi
Journal:  Oncoimmunology       Date:  2016-05-04       Impact factor: 8.110

6.  Structural requirements for the interaction of human IgM and IgA with the human Fcalpha/mu receptor.

Authors:  Ashfaq Ghumra; Jianguo Shi; Richard S Mcintosh; Ingunn B Rasmussen; Ranveig Braathen; Finn-Eirik Johansen; Inger Sandlie; Patricia K Mongini; Thomas Areschoug; Gunnar Lindahl; Melanie J Lewis; Jenny M Woof; Richard J Pleass
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

7.  Identification of residues in the Cmu4 domain of polymeric IgM essential for interaction with Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1).

Authors:  Ashfaq Ghumra; Jean-Philippe Semblat; Richard S McIntosh; Ahmed Raza; Ingunn B Rasmussen; Ranveig Braathen; Finn-Eirik Johansen; Inger Sandlie; Patricia K Mongini; J Alexandra Rowe; Richard J Pleass
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

8.  Engineering sperm-binding IgG antibodies for the development of an effective nonhormonal female contraception.

Authors:  Bhawana Shrestha; Alison Schaefer; Yong Zhu; Jamal Saada; Timothy M Jacobs; Elizabeth C Chavez; Stuart S Olmsted; Carlos A Cruz-Teran; Gabriela Baldeon Vaca; Kathleen Vincent; Thomas R Moench; Samuel K Lai
Journal:  Sci Transl Med       Date:  2021-08-11       Impact factor: 17.956

9.  Multimerization is required for antigen binding activity of an engineered IgM/IgG chimeric antibody recognizing a skin-related antigen.

Authors:  Kwesi Teye; Koji Hashimoto; Sanae Numata; Kunihiro Ohta; Marek Haftek; Takashi Hashimoto
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

10.  Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions.

Authors:  O S Qureshi; T F Rowley; F Junker; S J Peters; S Crilly; J Compson; A Eddleston; H Björkelund; K Greenslade; M Parkinson; N L Davies; R Griffin; T L Pither; K Cain; L Christodoulou; L Staelens; E Ward; J Tibbitts; A Kiessling; B Smith; F R Brennan; M Malmqvist; F Fallah-Arani; D P Humphreys
Journal:  Sci Rep       Date:  2017-12-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.